All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Cellaïon SA
Enrolment target
132
Start
26 Jul 2022
Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF)ACLF combines an acute deterioration of liver function in an individual with pre-existing chronic liver disease and extrahepatic organ failures characterized by high short-term mortality (30-40% at 28 days). The development of ACLF is associated with exacerbated systemic inflammation that may indeed cause organ failures.
What is this study about?
Survival at Day 90: Whether the patients are still alive will be recorded up to Day 90. Time and reason of death will be recorded.
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (14)
- —Denmark
- —Poland
- —Bulgaria
- —Netherlands
- —Slovakia
- —Latvia
- —Lithuania
- —Germany
- —Belgium
- —Austria
- —France
- —Estonia
+2 more sites — see the official record for the full list.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.